Pharma Focus Asia
KP - Choose our fully recyclable blister films

Novel Retevmo® (selpercatinib) Developed for Advanced or Metastatic Solid Tumors

Eli Lilly and Company developed novel Retevmo® (selpercatinib, 40 mg & 80 mg capsules) for the treatment of Advanced or Metastatic Solid Tumors in adults.

Retevmo is the novel and only approved RET inhibitor to receive both tumor-agnostic accelerated approval and traditional approval in NSCLC, thus providing meaningful clinical benefit for patients across diverse tumor types.

Retevmo is an oral prescription medicine, 120 mg or 160 mg applicable for individuals weighing (<50 kg or ≥50 kg, respectively), taken twice daily until disease progression or unacceptable toxicity.

Retevmo (selpercatinib), a selective and potent RET kinase inhibitor affects both tumor cells and healthy cells, resulting in side effects.

Retevmo® is indicated for patients with locally advanced or metastatic solid tumors with a rearranged during transfection (RET) gene fusion having progressed on or following prior systemic treatment or applicable for individuals who have left with no alternative treatment options. There has been a significant shift in the treatment paradigm for patients with RET-altered cancers since its approval.

U.S. Food and Drug Administration (FDA) has granted approval to Retevmo® (selpercatinib) for adult patients with locally advanced or metastatic solid tumors.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayThermo Fisher Scientific - PeptonesMerck - Mobius® products5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023CHEMICAL INDONESIA 2024INALAB 2024